OS Therapies (OSTX) said Wednesday its phase 2 OST-HER2 trial of an experimental treatment for lung metastatic osteosarcoma showed statistically significant results for the primary goal of 12-month event-free survival.
The company said the interim data from the ongoing 3-year overall survival secondary endpoint showed a strong trend in favor of the company's therapy in patients at both the 1-year and 2-year time points.
It added that all patients who reached the 12-month event-free survival endpoint remained alive.
"We are preparing to engage with the U.S. FDA on an accelerated pathway for approval in this extremely challenging indication," Paul Romness, MHP, Chair & CEO of OS Therapies, said.
Shares of the company rose more than 60% in premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。